Cargando…
Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment
Aggressive pelvic angiomyxoma is a very rare mesenchymal tumor that is usually diagnosed in premenopausal female patients. The current mainly reported treatment is wide surgical excision. Other treatment options, such as radiotherapy and hormonal therapy, have been suggested as potential alternative...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559397/ https://www.ncbi.nlm.nih.gov/pubmed/31245206 http://dx.doi.org/10.7759/cureus.4419 |
_version_ | 1783425822173954048 |
---|---|
author | Hajjar, Roy Alharthi, Mohammed Richard, Carole Gougeon, François Loungnarath, Rasmy |
author_facet | Hajjar, Roy Alharthi, Mohammed Richard, Carole Gougeon, François Loungnarath, Rasmy |
author_sort | Hajjar, Roy |
collection | PubMed |
description | Aggressive pelvic angiomyxoma is a very rare mesenchymal tumor that is usually diagnosed in premenopausal female patients. The current mainly reported treatment is wide surgical excision. Other treatment options, such as radiotherapy and hormonal therapy, have been suggested as potential alternatives. A 61-year-old postmenopausal female patient presented with hematuria that led to the identification of a perirectal mass on abdominopelvic imaging. A 46-year-old female patient presented with a perineal mass of unknown etiology. Despite extensive investigations, the diagnosis could not be confirmed before surgical resection in both patients. Surgical excisions were performed and revealed the presence of an aggressive angiomyxoma with positive estrogen and progesterone tumoral receptors in both cases. Radiological and clinical recurrence was noted in one patient. Tumor regression was noted in this patient after treatment with a luteinizing hormone-releasing hormone (LHRH) agonist with long-term remission. The diagnosis of a perirectal aggressive angiomyxoma is an exceedingly rare event. Preoperative biopsy and pathological diagnosis are challenging and often yields poor results. Its slow growth and expression of hormonal receptors make noninvasive therapeutic strategies, such as radiotherapy, gonadotropin-releasing hormone agonists, or even watchful waiting, valid options in selected patients. Due to the lack of reported cases, the best treatment has yet to be elucidated. |
format | Online Article Text |
id | pubmed-6559397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-65593972019-06-26 Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment Hajjar, Roy Alharthi, Mohammed Richard, Carole Gougeon, François Loungnarath, Rasmy Cureus Obstetrics/Gynecology Aggressive pelvic angiomyxoma is a very rare mesenchymal tumor that is usually diagnosed in premenopausal female patients. The current mainly reported treatment is wide surgical excision. Other treatment options, such as radiotherapy and hormonal therapy, have been suggested as potential alternatives. A 61-year-old postmenopausal female patient presented with hematuria that led to the identification of a perirectal mass on abdominopelvic imaging. A 46-year-old female patient presented with a perineal mass of unknown etiology. Despite extensive investigations, the diagnosis could not be confirmed before surgical resection in both patients. Surgical excisions were performed and revealed the presence of an aggressive angiomyxoma with positive estrogen and progesterone tumoral receptors in both cases. Radiological and clinical recurrence was noted in one patient. Tumor regression was noted in this patient after treatment with a luteinizing hormone-releasing hormone (LHRH) agonist with long-term remission. The diagnosis of a perirectal aggressive angiomyxoma is an exceedingly rare event. Preoperative biopsy and pathological diagnosis are challenging and often yields poor results. Its slow growth and expression of hormonal receptors make noninvasive therapeutic strategies, such as radiotherapy, gonadotropin-releasing hormone agonists, or even watchful waiting, valid options in selected patients. Due to the lack of reported cases, the best treatment has yet to be elucidated. Cureus 2019-04-09 /pmc/articles/PMC6559397/ /pubmed/31245206 http://dx.doi.org/10.7759/cureus.4419 Text en Copyright © 2019, Hajjar et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Obstetrics/Gynecology Hajjar, Roy Alharthi, Mohammed Richard, Carole Gougeon, François Loungnarath, Rasmy Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment |
title | Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment |
title_full | Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment |
title_fullStr | Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment |
title_full_unstemmed | Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment |
title_short | Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment |
title_sort | pelvic aggressive angiomyxoma: major challenges in diagnosis and treatment |
topic | Obstetrics/Gynecology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559397/ https://www.ncbi.nlm.nih.gov/pubmed/31245206 http://dx.doi.org/10.7759/cureus.4419 |
work_keys_str_mv | AT hajjarroy pelvicaggressiveangiomyxomamajorchallengesindiagnosisandtreatment AT alharthimohammed pelvicaggressiveangiomyxomamajorchallengesindiagnosisandtreatment AT richardcarole pelvicaggressiveangiomyxomamajorchallengesindiagnosisandtreatment AT gougeonfrancois pelvicaggressiveangiomyxomamajorchallengesindiagnosisandtreatment AT loungnarathrasmy pelvicaggressiveangiomyxomamajorchallengesindiagnosisandtreatment |